Disease Proteomics Laboratory, Department of Zoology, Bharathiar University, Coimbatore, TN, India.
Eur Rev Med Pharmacol Sci. 2021 Mar;25(6):2748-2751. doi: 10.26355/eurrev_202103_25438.
COVID-19 is an acute respiratory infectious disease caused by SARS-COV 2 (Severe Acute Respiratory Syndrome Coronavirus) that has become a global pandemic. COVID-19 mainly causes the respiratory complications of Acute Respiratory Distress Syndrome (ARDS), cytokine storm, and severe immune disruptions. The assays depict that though people recuperate from COVID-19, there are still symptoms that persists in the body causing discomfort, which is the consequence of the viral infection due to severe immune disruptions. Upon various difficulties of post COVID-19, the pulmonary fibrosis is the stumbling block in the lungs causing severe damage. In this review, we have shown the effectiveness and importance of the Hepatocyte Growth Factor (HGF) secreted by Mesenchymal Stem Cell (MSC) therapy on selective stoppage of the Transforming Growth Factor-Beta (TGF-β) signalling pathway by causing immunomodulatory effects that ameliorate the pulmonary fibrosis through paracrine signalling. However, more pilot studies have to be carried out to determine the efficacy and outcomes of the re-emerging complication.
新型冠状病毒肺炎（Corona Virus Disease 2019，COVID-19）是由严重急性呼吸综合征冠状病毒 2 型（severe acute respiratory syndrome coronavirus 2，SARS-CoV-2）引起的急性呼吸道传染病，现已成为全球性大流行疾病。COVID-19 主要导致急性呼吸窘迫综合征（acute respiratory distress syndrome，ARDS）、细胞因子风暴和严重免疫紊乱等呼吸系统并发症。研究表明，尽管人们从 COVID-19 中康复，但仍有持续存在于体内的症状，导致不适，这是由于严重免疫紊乱导致的病毒感染的后果。在应对各种 COVID-19 后问题时，肺纤维化是肺部的绊脚石，导致严重损伤。在这篇综述中，我们展示了间充质干细胞（mesenchymal stem cell，MSC）分泌的肝细胞生长因子（hepatocyte growth factor，HGF）通过免疫调节作用，选择性阻断转化生长因子-β（transforming growth factor-β，TGF-β）信号通路的有效性和重要性，从而减轻肺纤维化。通过旁分泌信号。然而，还需要进行更多的初步研究，以确定这种新出现的并发症的疗效和结果。
